Ventus Therapeutics is a drug discovery company focused on developing novel small molecule therapeutics targeting innate immunity pathways, particularly the NLRP3 inflammasome and gasdermin proteins. The company's innovative approach to modulating pyroptosis and inflammatory cell death positions it uniquely in the neurodegenerative disease space.
| Attribute | Value |
|---|---|
| Founded | 2018 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Dr. Juan Andres |
| Funding | Series B ($70M, 2023) |
| Focus | NLRP3 and gasdermin inhibitors |
| Stage | Preclinical |
Ventus Therapeutics was founded based on research from leading academic institutions:
The company's platform leverages cryo-EM structures of NLRP3 and gasdermins to design highly selective inhibitors.
Ventus's platform targets two critical nodes in the inflammatory cascade:
This dual approach provides broader anti-inflammatory effects than single-target approaches.
In Parkinson's disease, both NLRP3 activation and gasdermin-mediated pyroptosis contribute to dopaminergic neuron death:
Alpha-synuclein aggregation → Microglial NLRP3 activation → Caspase-1 activation
↓
Gasdermin D cleavage
↓
Pyroptotic cell death
↓
Dopaminergic neuron loss
Ventus's inhibitors block this pathway at multiple points, potentially providing enhanced neuroprotection.
| Program | Target | Indication | Stage | Status |
|---|---|---|---|---|
| VTS-101 | NLRP3 | Parkinson's disease | Preclinical | Lead optimization |
| VTS-202 | Gasdermin D | Neurodegeneration | Discovery | Hit-to-lead |
| VTS-303 | NLRP3/Gasdermin | Inflammatory diseases | Discovery | Early stage |
VTS-101 is Ventus's lead program for Parkinson's disease:
Preclinical data in 6-OHDA rat model showed:
VTS-202 targets gasdermin D, the effector protein of pyroptosis:
This approach may provide benefit even when NLRP3 is partially active.
| Round | Amount | Year | Investors |
|---|---|---|---|
| Series A | $25M | 2019 | Versant Ventures, Third Rock |
| Series B | $70M | 2023 | Google Ventures, Andreessen Horowitz, ARCH Venture |
The Parkinson's disease neuroinflammation market represents a significant opportunity:
| Parameter | Value |
|---|---|
| Global PD patients | ~10 million |
| Target population | Early-to-mid stage patients with inflammation biomarkers |
| Market potential | $3-7B annually |
| Development timeline | 4-6 years to potential approval |
Ventus competes with several companies in the NLRP3 space, but its gasdermin program provides a differentiated approach:
| Company | Focus | Differentiation |
|---|---|---|
| Ventus | NLRP3 + Gasdermin | Dual mechanism |
| Olacteant | NLRP3 (Dapansutrile) | Clinical data |
| NodThera | NLRP3 | CNS expertise |
| IFM/BMS | NLRP3 | Big pharma resources |
| Novartis | NLRP3 (DFV890) | Phase 1 data |